Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non–ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY

article by Chee Tang Chin et al published July 2010 in American Heart Journal

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non–ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.AHJ.2010.04.022
P698PubMed publication ID20598967

P50authorHarvey WhiteQ1587897
Dorairaj PrabhakaranQ37390473
Matthew T RoeQ64684757
Yuliya LokhnyginaQ82040206
P2093author name stringEileen Brown
Paul W. Armstrong
Chee Tang Chin
E. Magnus Ohman
Keith A.A. Fox
Helene Petitjean
Debra A. Marshall
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectpatientQ181600
clopidogrelQ410237
myocardial infarctionQ12152
P304page(s)16-22.e1
P577publication date2010-07-01
P1433published inAmerican Heart JournalQ2227156
P1476titleStudy design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non–ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY
P478volume160

Reverse relations

cites work (P2860)
Q38475429A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel
Q38391208A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention
Q37998114Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines
Q41620962Adequate Platelet Function Inhibition Confirmed by Two Inductive Agents Predicts Lower Recurrence of Ischemic Stroke/Transient Ischemic Attack.
Q38101275Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents
Q35752619Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Q37914924Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents
Q37965609Antiplatelet therapy in acute coronary syndromes.
Q37997963Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus
Q39161550Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial
Q36484993Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome
Q39768278Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial
Q90146028Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome
Q57243374Atherothrombosis and the role of antiplatelet therapy
Q37403998Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes
Q45894982Contemporary roles of registries in clinical cardiology: when do we need randomized trials?
Q37913974Cost-effectiveness of oral antiplatelet agents--current and future perspectives
Q90613054Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes
Q38005018Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials
Q39550267Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Q55074433Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Q40825574Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients
Q37949587Emerging therapies for acute coronary syndromes
Q50279616Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial
Q35135852Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome
Q41528609Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial
Q38025446Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel
Q36141930Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes
Q42185272Oral antiplatelet therapy in acute coronary syndromes: update 2012.
Q39635786Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention
Q37969927P2Y12 platelet inhibition in clinical practice
Q51539033P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.
Q82791112Percutaneous coronary intervention in the elderly
Q38084549Perioperative management of antiplatelet therapy in patients with drug-eluting stents.
Q37142852Personalized vascular medicine: individualizing drug therapy
Q38113231Pharmacokinetic considerations for antithrombotic therapies in stroke
Q89903377Pharmacological interventions for heart failure in people with chronic kidney disease
Q57252716Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial
Q37907902Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Q57243369Quelle place pour les nouveaux anti-agrégants plaquettaires dans la stratégie thérapeutique ?
Q35067126Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting
Q37556037Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
Q37953259Role of antiplatelet therapy in secondary prevention of acute coronary syndrome
Q36163681ST Elevation Myocardial Infarction in the elderly
Q37925009TRITON and beyond: new insights into the profile of prasugrel
Q26829746The year in non-ST-segment elevation acute coronary syndrome
Q41817424Towards personalized medicine based on platelet function testing for stent thrombosis patients
Q38005621Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?

Search more.